Therapies that aim to block TGF-β signaling in the tumor microenvironment are of high interest and have generated favorable responses in clinical trials, yet the importance of TGF-β signaling on CD8+ TIL in the tumor microenvironment remains to be determined [159, 160]. Here, TGFB1 is linked to neoplasm.